WEBVTT

00:00:02.200 --> 00:00:05.555
Tesamorelin begins our growth and hormonal
signaling collection

00:00:05.580 --> 00:00:09.295
with fat that a bathroom scale cannot
distinguish.

00:00:09.320 --> 00:00:12.900
Visceral fat surrounds internal organs.

00:00:13.720 --> 00:00:16.380
Subcutaneous fat lies beneath the skin.

00:00:17.180 --> 00:00:20.040
Measuring one is different from measuring
total body weight.

00:00:20.620 --> 00:00:24.995
Developed by Theratechnologies in
Montreal, tesamorelin is a

00:00:25.020 --> 00:00:28.495
modified, forty-four-amino-acid version of

00:00:28.520 --> 00:00:30.280
growth-hormone-releasing hormone.

00:00:31.080 --> 00:00:34.435
The United States first approved Egrifta
in twenty ten

00:00:34.460 --> 00:00:39.655
for excess abdominal fat in adults with
HIV-associated

00:00:39.680 --> 00:00:41.420
lipodystrophy.

00:00:41.880 --> 00:00:44.795
It acts at the pituitary, encouraging the
body to

00:00:44.820 --> 00:00:49.095
release growth hormone and increasing
IGF-1.

00:00:49.120 --> 00:00:53.095
It stimulates a signaling pathway rather
than supplying growth

00:00:53.120 --> 00:00:54.280
hormone itself.

00:00:55.020 --> 00:00:58.835
In a randomized trial led by Julian Falutz
and

00:00:58.860 --> 00:01:02.635
colleagues, four hundred twelve adults
with HIV and abdominal

00:01:02.660 --> 00:01:07.975
fat accumulation received tesamorelin or
placebo for twenty-six

00:01:08.000 --> 00:01:09.000
weeks.

00:01:09.780 --> 00:01:14.195
CT measurements showed average visceral
fat falling fifteen point

00:01:14.220 --> 00:01:18.435
two percent with tesamorelin, while
placebo increased five

00:01:18.460 --> 00:01:19.400
percent.

00:01:19.760 --> 00:01:23.255
These were changes in a defined tissue
measurement, not

00:01:23.280 --> 00:01:25.220
percentages of total body weight.

00:01:25.880 --> 00:01:27.340
The approved use is specific.

00:01:28.120 --> 00:01:31.100
Tesamorelin is not indicated for
weight-loss management.

00:01:31.780 --> 00:01:36.755
Elevated IGF-1, fluid retention and
glucose intolerance

00:01:36.780 --> 00:01:38.260
require attention.

00:01:39.240 --> 00:01:42.755
Active cancer and pregnancy are among its
contraindications.

00:01:42.780 --> 00:01:47.220
Long-term cardiovascular safety has not
been established.

00:01:48.080 --> 00:01:51.815
Connect the medicine to its studied
population and measured

00:01:51.840 --> 00:01:52.560
outcome.

00:01:53.260 --> 00:01:56.895
These findings do not establish an
anti-aging or bodybuilding

00:01:56.920 --> 00:01:57.495
benefit.

00:01:57.520 --> 00:02:00.960
World Peptide Foundation.

00:02:01.820 --> 00:02:03.715
Peptides in 2.

00:02:03.740 --> 00:02:04.840
Every experience matters.